Investors / United States / ARCH Venture Partners
ARCH Venture Partners
Venture capital · Chicago, IL, United States · North America
ARCH Venture Partners is a venture firm that founds and builds companies based on science and revolutionary technologies. It invests as little as $50K and as much as hundreds of millions of dollars per company and takes a long-term, flexible approach to building them.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechhealthcaredeep techcompany formation
Your fit with ARCH Venture Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsARCH Venture Partners lists 113 checked portfolio companies on its own site and is named in 40 funding rounds, 17 of them as lead. Its most frequent entry is Series A, 34% of the companies with a known first round. Its largest themes are Healthcare & Biotech (91%), AI & Machine Learning (3%) and Industrial & Manufacturing (2%). 88% of its companies are based in United States. It invests most often alongside F-Prime Capital, Casdin Capital and Foresite Capital.
Counts come from funding rounds that name ARCH Venture Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not ARCH Venture Partners' whole history. Rounds on record name 37 companies; its own site lists 113. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundARCH Venture Partners does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 11% |
| Series A | 34% |
| Series B | 34% |
| Growth | 20% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 1 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 2 | 1 |
| '24 | 2 | 1 |
| '25 | 13 | 5 |
| '26 | 22 | 10 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 96th | 113 companies |
| Recent activity | 99th | 25 rounds in 12 months |
| Early stage | 55th | 11% of entries at pre-seed or seed |
| Evidence | 89th | 18% of companies confirmed by a round |
| Sector focus | 96th | 91% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| F-Prime Capital | 15 |
| Casdin Capital | 14 |
| Foresite Capital | 9 |
| GV | 9 |
| General Catalyst | 9 |
| SoftBank Vision Fund | 8 |
| Catalio Capital Management | 6 |
| RA Capital | 6 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers10694%
- No longer answers00%
- Points to another company76%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 91% | 15% |
| AI & Machine Learning | 3% | 18% |
| Industrial & Manufacturing | 2% | 7% |
| Fintech | 2% | 12% |
| Real Estate & Construction | 1% | 3% |
| Cybersecurity | 1% | 4% |
| Media & Entertainment | 1% | 4% |
Co-investor network
who it backs companies with, and who they back togetherCompare ARCH Venture Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with ARCH Venture Partners| Date | Company | Stage |
|---|---|---|
| 13 Oct 2026 | Series B | |
| 8 Oct 2026 | Series B Led | |
| 22 Sept 2026 | Series A Led | |
| 9 Sept 2026 | Series C+ | |
| 8 Sept 2026 | Series B | |
| 18 Aug 2026 | Series A Led | |
| 5 Aug 2026 | Series C+ | |
| 7 Jul 2026 | Series A Led |
Round details for ARCH Venture Partners
Amounts, full round histories and every co-investor in ARCH Venture Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
113 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Portfolio page | ||||
| Accompany Health provides medical, mental health, and social care, all covered by insurance. | Healthcare & Biotech | Portfolio page | ||
| Aera Therapeutics develops delivery platforms for genetic medicines | Healthcare & Biotech | Portfolio page | ||
| Agios develops therapies for people with rare diseases, with a focus on hemolytic and acquired anemias. | Healthcare & Biotech | Portfolio page | ||
| Airna is developing novel medicines with the potential to deliver functional cures for patients using RNA editing technology. | Healthcare & Biotech | Portfolio page | ||
| Akamis Bio is working to advance the standard of care in colorectal cancer by developing oncolytic immunotherapies | Healthcare & Biotech | Portfolio page | ||
| Aledade provides actionable insights and expert support for clinicians to keep their patients healthy while generating sustainable revenue through its accountable care organizations (ACOs). | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Alnylam Pharmaceuticals develops RNAi therapeutics. | Healthcare & Biotech | Portfolio page | ||
| Altos Labs is focused on understanding how to translate the science of cell rejuvenation to help people live healthier lives. | Healthcare & Biotech | Portfolio page | ||
| Arbor Biotechnologies develops novel gene editing treatments for people living with genetic disease | Healthcare & Biotech | Portfolio page | ||
| Arsenal Biosciences, Inc. is a cell therapy company that discovers and develops next-generation in vivo T cell therapies to address chronic disease, including cancer and autoimmunity. | Healthcare & Biotech | Portfolio page | ||
| Aspen Neuroscience develops personalized cell therapies for Parkinson's disease using stem cell biology and genomics | Healthcare & Biotech | Nov 2025Series C+ | Page + round | |
Healthcare & BiotechIndustrial & Manufacturing | May 2025Seed | Funding round | ||
| Autobahn Therapeutics creates the next generation of regenerative medicines for the brain to improve life health for people affected by CNS disorders | Healthcare & Biotech | Portfolio page | ||
| Basking Biosciences is developing a targeted, highly specific, short-acting therapy with a direct-acting reversal agent to treat life-threatening clots | Healthcare & Biotech | Portfolio page | ||
| Beam Therapeutics is a company that develops precision genetic medicines using base editing technology | Healthcare & Biotech | Portfolio page | ||
| The company develops and sells synthetic biology products for human health, including cells and assays for various diseases and applications. | Healthcare & Biotech | Portfolio page | ||
| Boundless Bio develops therapies for patients with intractable oncogene amplified cancers. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page |
About this data
site last read 12 Nov 2026- Site
- archventure.com
- Last read
- 12 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 26 May 2020
- Companies checked
- 113
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get ARCH Venture Partners' profile as data
Pull ARCH Venture Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/archventure.com
# also
GET /v1/firms/archventure.com/portfolio
GET /v1/firms/archventure.com/coinvestors
GET /v1/firms/archventure.com/news